Luther King Capital Management (LKCM)’s Emergent Biosolutions EBS Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-110,491	Closed	-$10.3M	–	612
2021 Q1	$10.3M	Sell	110,491 -11,796	-10%	-$1.21M	0.06%	145
2020 Q4	$11M	Buy	122,287 +31,885	+35%	+$2.93M	0.06%	139
2020 Q3	$9.34M	Sell	90,402 -16,177	-15%	-$1.74M	0.06%	136
2020 Q2	$8.43M	Buy	106,579 +48,604	+84%	+$3.62M	0.06%	144
2020 Q1	$3.35M	Buy	57,975 +10,520	+22%	+$606K	0.03%	181
2019 Q4	$2.56M	Buy	47,455 +7,700	+19%	+$418K	0.02%	259
2019 Q3	$2.08M	Buy	39,755 +32,460	+445%	+$1.51M	0.02%	269
2019 Q2	$352K	Buy	+7,295	New	+$350K	﹤0.01%	443

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Luther King Capital Management (LKCM)'s EBS Position: Q2 2021 in Review

Luther King Capital Management (LKCM) sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 110,491 shares — an estimated $10.3M sold.

Luther King Capital Management (LKCM) first reported a position in EBS in Q2 2019 and held it in 8 quarters. The position peaked at $11M in Q4 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

Luther King Capital Management (LKCM) reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
Luther King Capital Management (LKCM) sold 110,491 Emergent Biosolutions shares in Q2 2021, an estimated $10.3M.
Luther King Capital Management (LKCM) first reported a position in Emergent Biosolutions in Q2 2019 and held it in 8 quarters.
Luther King Capital Management (LKCM)'s Emergent Biosolutions position peaked at $11M in Q4 2020.
290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q2 2021, filed 13 Aug 2021.